Issue 3/2022
Content (11 Articles)
Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions
- Ranolazine
- Leading Article
Islam Y. Elgendy, Lina Ya’Qoub, Kuan-Han Chen, Carl J. Pepine
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
- Open Access
- Naltrexone
- Review Article
Elizabeth M. Burnette, Steven J. Nieto, Erica N. Grodin, Lindsay R. Meredith, Brian Hurley, Karen Miotto, Artha J. Gillis, Lara A. Ray
Pharmacologic Management of Persistent Pain in Cancer Survivors
- Open Access
- Opioids
- Review Article
Paul Glare, Karin Aubrey, Amitabh Gulati, Yi Ching Lee, Natalie Moryl, Sarah Overton
Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature
- Glioblastoma
- Systematic Review
Luis F. Rendon, Ishaan A. Tewarie, David J. Cote, Aaron Gabriel, Timothy R. Smith, Marike L. D. Broekman, Rania A. Mekary
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases
- Metformin
- Original Research Article
Tian Li, Rui Providencia, Wenhua Jiang, Manling Liu, Lu Yu, Chunhu Gu, Alex Chia Yu Chang, Heng Ma
Ocrelizumab: A Review in Multiple Sclerosis
- Magnetic Resonance Imaging
- Adis Drug Evaluation
Yvette N. Lamb
Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
- Antidepressant Drugs
- Letter to the Editor
Mario Gennaro Mazza, Benedetta Vai, Livia De Picker, Francesco Benedetti, Raffaella Zanardi
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
- Mood Disorders
- Letter to the Editor
Eric J. Lenze, Angela M. Reiersen, Shelley N. Facente
Correction to: Ocular Toxicity of Targeted Anticancer Agents
- Edema
- Correction
Blake H. Fortes, Prashant D. Tailor, Lauren A. Dalvin